A detailed history of Great Point Partners LLC transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Great Point Partners LLC holds 1,016,375 shares of TCRX stock, worth $3.13 Million. This represents 2.34% of its overall portfolio holdings.

Number of Shares
1,016,375
Previous 940,831 8.03%
Holding current value
$3.13 Million
Previous $5.5 Million 8.03%
% of portfolio
2.34%
Previous 1.46%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$4.97 - $7.49 $375,453 - $565,824
75,544 Added 8.03%
1,016,375 $5.06 Million
Q2 2024

Aug 14, 2024

BUY
$5.85 - $9.51 $5.5 Million - $8.95 Million
940,831 New
940,831 $5.5 Million

Others Institutions Holding TCRX

About TScan Therapeutics, Inc.


  • Ticker TCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,929,800
  • Market Cap $58.3M
  • Description
  • TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...
More about TCRX
Track This Portfolio

Track Great Point Partners LLC Portfolio

Follow Great Point Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Great Point Partners LLC with notifications on news.